Bioxytran (BIXT) Liabilities and Shareholders Equity (2010 - 2026)
Bioxytran (BIXT) posted Liabilities and Shareholders Equity of $615253.0 for Q1 2026, down 6.57% sequentially from $658552.0 in Q4 2025, and up 352.22% YoY from $136052.0 in Q1 2025.
Bioxytran (BIXT) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Bioxytran has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $615253.0 in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 352.22% year-over-year to $615253.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 180.56% YoY) and the FY2025 annual result came in at $658552.0, up 374.82% from the prior year.
- Liabilities and Shareholders Equity eased to $615253.0 in Q1 2026 per BIXT's latest filing, from $658552.0 in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $807927.0 in Q1 2022 and troughed at $125540.0 in Q1 2024.
- A 5-year average of $303887.8 and a median of $159008.0 in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity tumbled 74.82% in 2023, then soared 374.82% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $370936.0 in 2022, then slumped by 62.42% to $139382.0 in 2023, then declined by 0.49% to $138694.0 in 2024, then jumped by 374.82% to $658552.0 in 2025, then dropped by 6.57% to $615253.0 in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $615253.0, $658552.0, and $156294.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 333,393.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 615,253.00 |
| Dec 31, 2025 | 658,552.00 |
| Sep 30, 2025 | 156,294.00 |
| Jun 30, 2025 | 147,501.00 |
| Mar 31, 2025 | 136,052.00 |
| Dec 31, 2024 | 138,694.00 |
| Sep 30, 2024 | 159,008.00 |
| Jun 30, 2024 | 128,553.00 |
| Mar 31, 2024 | 125,540.00 |
| Dec 31, 2023 | 139,382.00 |
| Sep 30, 2023 | 189,043.00 |
| Jun 30, 2023 | 143,061.00 |
| Mar 31, 2023 | 233,533.00 |
| Dec 31, 2022 | 370,936.00 |
| Sep 30, 2022 | 448,539.00 |
| Jun 30, 2022 | 568,225.00 |
| Mar 31, 2022 | 807,927.00 |
| Dec 31, 2021 | 119,290.00 |
| Sep 30, 2021 | 762,248.00 |
| Jun 30, 2021 | 906,297.00 |